Skip to main navigation

Immunocore

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analysts Coverage
Corporate Governance
Financials & Filings
- SEC Filings
- Annual Reports
IR Resources

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analysts Coverage
Corporate Governance
Financials & Filings
- SEC Filings
- Annual Reports
IR Resources

News Releases

Breadcrumb

Home /
Investor Relations /
News & Events /
News Releases

Year

9 September 2022

Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress

10 August 2022

Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update

3 August 2022

Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022

1 August 2022

Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

18 July 2022

Immunocore Announces $140 Million Private Placement Financing

11 July 2022

Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV

25 June 2022

Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™

9 June 2022

Immunocore Appoints Siddharth Kaul to its Board of Directors

8 June 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

6 June 2022

Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 11 - 20 of 159

Site - Shareholder Tools

Immunocore

Site - Footer Social

About us
Our science
Our therapy areas
For patients

News
Careers
Contact us

Privacy and Social Media Guidelines
Cookies
Payments and Disclosures
Clinical trials

©2023 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd